Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Ending Parkinson's

PDF is increasing investment in research, health care and patient leaders, then mobilizing them to work together toward the cure.

Learn More

Grant Programs

PDF has opened eight programs that provide critical funding for Parkinson's research.

Learn More

We Need You

People with Parkinson's are key partners in our work to solve, treat and end the disease.

Learn More

A New Home for Parkinson's Science

An open access journal, enabling professionals and people with PD to access the latest research.

Learn More
       

Alpha-Synuclein in Action

PDF-funded scientist-clinician Kateri Spinelli, Ph.D., is using cutting-edge technology to see how a potential culprit (the protein alpha-synuclein) works in Parkinson's disease.

Learn More 
Your Donations Make a Difference

Your support makes the research of Dr. Hess and Dr. Earhart possible, allowing us to learn about the role of genetics and the potential of exercise in Parkinson's.


Watch Our Video & Learn More

PD ExpertBriefing: Dealing with Dementia in PD 

Tuesday, March 1 (Online)

While many people with PD will experience some degree of mild cognitive change, it is estimated that at any given time, about one quarter to one third of people with PD are experiencing dementia. What should you know about dementia in PD? Find tips by joining a one­-hour online seminar led by PDF and Jennifer G. Goldman, M.D., M.S., Associate Professor, Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, PDF Research Center at Rush University Medical Center.

Click Here to Learn More

Community Events

View All Upcoming Events = PDF Sponsored Events

Potential New Therapy for Reducing Levodopa “Off-time”

January 31, 2016

According to the results of a phase III clinical trial, a drug called opicapone may provide a new option for reducing “wearing-off” periods for people with Parkinson’s who take levodopa. The researchers found that opicapone is modestly more effective than entacapone (Comtan®, also an ingredient in Stalevo®), the drug most commonly prescribed today for this purpose. It also offers the convenience of only one dose a day. The study appears in the December 22 online edition of The Lancet Neurology.

Learn More

View All News